Charles Baum, MD, PhD, currently serves as Chief Executive Officer and Board Member at Terremoto Biosciences, a position held since July 2023. Baum holds significant board roles, including Board Member and Chair of the Nominating and Governance Committee at PMV Pharmaceuticals, Inc., and Board Member and Chair of the Compensation Committee at Acrivon Therapeutics, Inc. Previous leadership experience includes founding Mirati Therapeutics, where Baum served as CEO and President from 2012 until its acquisition by Bristol-Myers Squibb in 2024. Additional board memberships include roles at ALX Oncology, Odyssey Therapeutics, and Poseida Therapeutics, among others. Baum's early career includes senior positions at Pfizer, where responsibilities encompassed leading oncology programs. Baum earned both MD and PhD degrees from Washington University School of Medicine in St. Louis.
This person is not in the org chart
This person is not in any teams
This person is not in any offices